Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase III study on the effect of bortezomib combined with adriamycin [doxorubicin], dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma

Next Previous
X
Search
Trial Profile

A randomized phase III study on the effect of bortezomib combined with adriamycin [doxorubicin], dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Filgrastim; Melphalan; Thalidomide; Vincristine
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Millennium

    • Most Recent Events

    • 14 Dec 2021 Results of Intergroup Analysis from phase III trials, HD4, MM5 and HD6 and European Myeloma Network (EMN) 02/ Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation (HOVON) 95 presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 06 Nov 2019 Results, long term follow up after median 137 months of Bortezomib-based induction and maintenance therapy assessing overall survival in the VAD arm versus PAD arm, released at the 61st Annual Meeting and Exposition of the American Society of Hematology
    • 04 Dec 2018 Results (n=354) assessing long term survival of Bortezomib in multiple myeloma in German patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top